The rationale behind this observation is unclear, and they suggest that children should be excluded from sepsis clinical trials involving PCSK9 inhibitors until the unknown effect of PCSK9 dysfunction in young children is clarified. This evidence concerns the gene PCSK9 and Sepsis.